We are analyzing https://link.springer.com/article/10.1007/bf00666588.

Title:
Finite proliferative lifespanin vitro of a human breast cancer cell strain isolated from a metastatic lymph node | Breast Cancer Research and Treatment
Description:
We recently described culture conditions that allow proliferation of metastatic human breast cancer cells from biopsy specimens of certain patient samples. These conditions resulted in the development of an immortalized cell strain designated SUM-44PE. These same culture conditions were used to isolate a human breast cancer cell strain from a metastatic lymph node of a separate breast cancer patient. The SUM-16LN human breast cancer cells isolated from this specimen were cultured either in serum-free medium or serum-containing medium supplemented with insulin and hydrocortisone. Unlike the SUM-44PE cells that have proliferated in culture continuously for over two years, SUM-16LN cells proliferated in culture for approximately 200 days and underwent 15 to 20 population doublings before undergoing cell senescence. No cells of this strain proliferated beyond passage 8. SUM-16LN cells were keratin-19 positive and had an aneuploid karyotype. These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Despite the presence of high levels of tyrosine phosphorylated EGF receptor in these cells, they proliferated in serum-free, EGF-free medium and did not secrete detectable levels of EGF-like mitogenic growth factor. In addition, these cells were potently growth inhibited by all concentrations of exogenous EGF tested and by the neutralizing EGF receptor antibody Mab 425. These results suggest that the high level of tyrosine phosphorylated EGF receptor present in these cells is the direct result of receptor overexpression and not the result of the presence of a simulatory ligand. Thus, SUM-16LN represents a human breast cancer cell strain that exhibited genetic and cellular characteristics of advanced human breast cancer cells. Nevertheless, these cells exhibited a finite proliferative lifespan in culture, suggesting that cellular immortalization is not a phenotype expressed by all human breast cancer cells.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Non-Profit & Charity
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,603,724 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, breast, cells, google, scholar, human, cell, growth, culture, article, ethier, receptor, res, factor, epithelial, vitro, strain, medium, egf, normal, mammary, ann, privacy, cookies, content, research, proliferative, metastatic, conditions, serumfree, epidermal, usa, primary, publish, search, mahacek, beer, frank, proliferation, sumln, proliferated, tyrosine, phosphorylated, access, carcinoma, potential, differential, oncogene, nature, rat,

Topics {✒️}

ej c-ha-ras oncogene supports long-term growth undergoing cell senescence cell lines derived egf-treated a431 cells month download article/chapter sum-16ln cells proliferated breast cancer cells human breast carcinomas epidermal growth factor sum-44pe cells sum-16ln cells sum-16ln represents serum-free culture conditions mitogenic growth factor growth factor interactions human esophageal adenocarcinomas privacy choices/manage cookies vitro growth access metastatic lymph node finite proliferative lifespan extended growth potential potently growth inhibited full article pdf breast cancer exogenous egf tested cellular immortalization european economic area monolayer cultures suitable increased phosphotyrosine content michigan medical center egf-free medium secrete detectable levels defined phenotypic traits intermolecular allosteric activation growth factor conditions privacy policy serum-free medium breast carcinomas accepting optional cookies cellular characteristics overexpress neu/erbb-2 cell biol 103 cell types cell physiol 132 cell cycle journal finder publish primary culture strain proliferated cancer res 41

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Finite proliferative lifespanin vitro of a human breast cancer cell strain isolated from a metastatic lymph node
         description:We recently described culture conditions that allow proliferation of metastatic human breast cancer cells from biopsy specimens of certain patient samples. These conditions resulted in the development of an immortalized cell strain designated SUM-44PE. These same culture conditions were used to isolate a human breast cancer cell strain from a metastatic lymph node of a separate breast cancer patient. The SUM-16LN human breast cancer cells isolated from this specimen were cultured either in serum-free medium or serum-containing medium supplemented with insulin and hydrocortisone. Unlike the SUM-44PE cells that have proliferated in culture continuously for over two years, SUM-16LN cells proliferated in culture for approximately 200 days and underwent 15 to 20 population doublings before undergoing cell senescence. No cells of this strain proliferated beyond passage 8. SUM-16LN cells were keratin-19 positive and had an aneuploid karyotype. These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Despite the presence of high levels of tyrosine phosphorylated EGF receptor in these cells, they proliferated in serum-free, EGF-free medium and did not secrete detectable levels of EGF-like mitogenic growth factor. In addition, these cells were potently growth inhibited by all concentrations of exogenous EGF tested and by the neutralizing EGF receptor antibody Mab 425. These results suggest that the high level of tyrosine phosphorylated EGF receptor present in these cells is the direct result of receptor overexpression and not the result of the presence of a simulatory ligand. Thus, SUM-16LN represents a human breast cancer cell strain that exhibited genetic and cellular characteristics of advanced human breast cancer cells. Nevertheless, these cells exhibited a finite proliferative lifespan in culture, suggesting that cellular immortalization is not a phenotype expressed by all human breast cancer cells.
         datePublished:
         dateModified:
         pageStart:267
         pageEnd:276
         sameAs:https://doi.org/10.1007/BF00666588
         keywords:
            human breast cancer
            immortalization
             in vitro growth
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:28
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Michael L. Mahacek
               affiliation:
                     name:The University of Michigan Medical Center
                     address:
                        name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David G. Beer
               affiliation:
                     name:The University of Michigan Medical Center
                     address:
                        name:Department of Surgery, The University of Michigan Medical Center, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas S. Frank
               affiliation:
                     name:The University of Michigan Medical Center
                     address:
                        name:Department of Pathology, The University of Michigan Medical Center, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen P. Ethier
               affiliation:
                     name:The University of Michigan Medical Center
                     address:
                        name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Finite proliferative lifespanin vitro of a human breast cancer cell strain isolated from a metastatic lymph node
      description:We recently described culture conditions that allow proliferation of metastatic human breast cancer cells from biopsy specimens of certain patient samples. These conditions resulted in the development of an immortalized cell strain designated SUM-44PE. These same culture conditions were used to isolate a human breast cancer cell strain from a metastatic lymph node of a separate breast cancer patient. The SUM-16LN human breast cancer cells isolated from this specimen were cultured either in serum-free medium or serum-containing medium supplemented with insulin and hydrocortisone. Unlike the SUM-44PE cells that have proliferated in culture continuously for over two years, SUM-16LN cells proliferated in culture for approximately 200 days and underwent 15 to 20 population doublings before undergoing cell senescence. No cells of this strain proliferated beyond passage 8. SUM-16LN cells were keratin-19 positive and had an aneuploid karyotype. These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Despite the presence of high levels of tyrosine phosphorylated EGF receptor in these cells, they proliferated in serum-free, EGF-free medium and did not secrete detectable levels of EGF-like mitogenic growth factor. In addition, these cells were potently growth inhibited by all concentrations of exogenous EGF tested and by the neutralizing EGF receptor antibody Mab 425. These results suggest that the high level of tyrosine phosphorylated EGF receptor present in these cells is the direct result of receptor overexpression and not the result of the presence of a simulatory ligand. Thus, SUM-16LN represents a human breast cancer cell strain that exhibited genetic and cellular characteristics of advanced human breast cancer cells. Nevertheless, these cells exhibited a finite proliferative lifespan in culture, suggesting that cellular immortalization is not a phenotype expressed by all human breast cancer cells.
      datePublished:
      dateModified:
      pageStart:267
      pageEnd:276
      sameAs:https://doi.org/10.1007/BF00666588
      keywords:
         human breast cancer
         immortalization
          in vitro growth
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:28
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Michael L. Mahacek
            affiliation:
                  name:The University of Michigan Medical Center
                  address:
                     name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David G. Beer
            affiliation:
                  name:The University of Michigan Medical Center
                  address:
                     name:Department of Surgery, The University of Michigan Medical Center, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas S. Frank
            affiliation:
                  name:The University of Michigan Medical Center
                  address:
                     name:Department of Pathology, The University of Michigan Medical Center, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen P. Ethier
            affiliation:
                  name:The University of Michigan Medical Center
                  address:
                     name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:28
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Michigan Medical Center
      address:
         name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
         type:PostalAddress
      name:The University of Michigan Medical Center
      address:
         name:Department of Surgery, The University of Michigan Medical Center, Ann Arbor, USA
         type:PostalAddress
      name:The University of Michigan Medical Center
      address:
         name:Department of Pathology, The University of Michigan Medical Center, Ann Arbor, USA
         type:PostalAddress
      name:The University of Michigan Medical Center
      address:
         name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Michael L. Mahacek
      affiliation:
            name:The University of Michigan Medical Center
            address:
               name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
               type:PostalAddress
            type:Organization
      name:David G. Beer
      affiliation:
            name:The University of Michigan Medical Center
            address:
               name:Department of Surgery, The University of Michigan Medical Center, Ann Arbor, USA
               type:PostalAddress
            type:Organization
      name:Thomas S. Frank
      affiliation:
            name:The University of Michigan Medical Center
            address:
               name:Department of Pathology, The University of Michigan Medical Center, Ann Arbor, USA
               type:PostalAddress
            type:Organization
      name:Stephen P. Ethier
      affiliation:
            name:The University of Michigan Medical Center
            address:
               name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
      name:Department of Surgery, The University of Michigan Medical Center, Ann Arbor, USA
      name:Department of Pathology, The University of Michigan Medical Center, Ann Arbor, USA
      name:Department of Radiation Oncology, Division of Cancer Biology, The University of Michigan Medical Center, Ann Arbor, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(56)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.31s.

LINK . SPRINGER . COM {}